MannKind (MNKD – Research Report) received a Buy rating and a $6.50 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday at $3.78.
Brayer covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Alnylam Pharma, and BioMarin Pharmaceutical. According to TipRanks, Brayer has an average return of 1.1% and a 59.38% success rate on recommended stocks.
MannKind has an analyst consensus of Strong Buy, with a price target consensus of $6.13.
See Insiders’ Hot Stocks on TipRanks >>
MNKD market cap is currently $957M and has a P/E ratio of -30.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind (MNKD) Company Description:
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
- MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
- Is MNKD a Buy, Before Earnings?
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
- MannKind says INHALE-1 study now fully enrolled
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
